Description
Key facts
Cell type:MCF7,
Species or organism:Human,
Tissue:Breast,
Knockout validation:Next Generation Sequencing,Western blot,
Mutation description:Knockout achieved by CRISPR/Cas9; X = 1 bp insertion; Frameshift: 100%,
Disease:Adenocarcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-SCARB2, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Next Generation Sequencing, Western blot, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
LIMPII also known as LIMP-2 is a lysosomal membrane protein involved in the transport and degradation processes within cells. It has an approximate molecular mass of 54 kDa. LIMPII is mainly expressed in the lysosomal membranes of a variety of tissues notably in the kidney liver and spleen. Its structural characteristics enable it to function effectively within these cellular organelles delivering enzymes and other molecules essential for cellular maintenance and function.
Biological function summary
The protein plays a critical role in lipid and protein degradation and helps maintain cellular homeostasis. As part of the lysosomal membrane LIMPII facilitates the uptake and processing of large biomolecules into the lysosome. It functions as a receptor for the uptake of β-glucocerebrosidase forming a complex to assist in its proper delivery from the endoplasmic reticulum to the lysosomes. This receptor-ligand relationship ensures efficient enzymatic activity necessary for lipid metabolism.
Pathways
One finds that LIMPII participates in the sphingolipid metabolism pathway and is vital for glucosylceramide catabolism. It interacts with glucocerebrosidase in this pathway which plays a significant role in the metabolism of glycosphingolipids. Another pathway where LIMPII has importance is the autophagy pathway where it contributes to the fusion of autophagosomes with lysosomes. Its activity supports the turnover of cellular components maintaining cellular metabolic balance.
LIMPII's dysfunction has links to Gaucher's disease and atherosclerosis. Both conditions relate to improper lipid metabolism. In Gaucher's disease the interaction between LIMPII and glucocerebrosidase becomes disrupted leading to lysosomal storage issues. In contrast altered expressions of LIMPII correlate with atherosclerosis possibly due to its role in lipid processing. These associations suggest that LIMPII could be a significant factor in therapeutic approaches for these diseases.
